• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Photoallergic dermatitis and vitiligo-like lesion in a patient with metastatic breast cancer using ribociclib.

作者信息

Menteşoğlu Dilek

机构信息

Department of Dermatology and Venereology, Acıbadem Eskişehir Hospital, Eskişehir, Turkey.

出版信息

Indian J Pharmacol. 2023 May-Jun;55(3):190-191. doi: 10.4103/ijp.ijp_85_23.

DOI:10.4103/ijp.ijp_85_23
PMID:37555416
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10501537/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f015/10501537/b6deaa52238c/IJPharm-55-190-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f015/10501537/b6deaa52238c/IJPharm-55-190-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f015/10501537/b6deaa52238c/IJPharm-55-190-g001.jpg

相似文献

1
Photoallergic dermatitis and vitiligo-like lesion in a patient with metastatic breast cancer using ribociclib.一名使用瑞博西尼的转移性乳腺癌患者出现光变应性皮炎和白癜风样病变。
Indian J Pharmacol. 2023 May-Jun;55(3):190-191. doi: 10.4103/ijp.ijp_85_23.
2
Drug induced vitiligo-like depigmentation from a CDK 4/6 inhibitor.CDK4/6 抑制剂诱导的药物性白癜风样脱色。
Asia Pac J Clin Oncol. 2022 Apr;18(2):e154-e156. doi: 10.1111/ajco.13585. Epub 2021 Jun 28.
3
Ribociclib Lengthens Breast Cancer Survival.瑞博西利延长乳腺癌患者生存期。
Cancer Discov. 2016 Dec;6(12):1299. doi: 10.1158/2159-8290.CD-NB2016-138. Epub 2016 Nov 3.
4
Vitiligo in the affected breast during neo-adjuvant chemotherapy for breast cancer.乳腺癌新辅助化疗期间患侧乳房出现白癜风。
Breast Cancer Res Treat. 2009 Sep;117(1):197-8. doi: 10.1007/s10549-008-0074-6. Epub 2008 Jul 1.
5
Quantification of Economic Impact of Drug Wastage in Oral Oncology Medications: Comparison of 3 Methods Using Palbociclib and Ribociclib in Advanced or Metastatic Breast Cancer.口腔肿瘤药物中药物浪费的经济影响量化：使用帕博西尼和瑞博西尼治疗晚期或转移性乳腺癌的 3 种方法比较。
J Manag Care Spec Pharm. 2019 Aug;25(8):859-866. doi: 10.18553/jmcp.2019.25.8.859.
6
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.来曲唑联合瑞博西利与来曲唑联合帕博西利及来曲唑单药治疗激素受体阳性、人表皮生长因子受体 2 阴性的绝经后晚期或转移性乳腺癌的成本-效果分析：美国支付者视角。
J Manag Care Spec Pharm. 2018 Jun;24(6):514-523. doi: 10.18553/jmcp.2018.24.6.514.
7
Ribociclib Shows Sustained Overall Survival Benefit in Postmenopausal Women with HR+/HER2- Advanced Breast Cancer.瑞博西利为绝经后激素受体阳性、人表皮生长因子受体 2 阴性的晚期乳腺癌患者带来持续的总生存获益。
Oncologist. 2021 Jul;26 Suppl 3(Suppl 3):S7-S8. doi: 10.1002/onco.13866. Epub 2021 Jun 21.
8
Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.来曲唑联合内分泌治疗与安慰剂联合内分泌治疗用于激素受体阳性、人表皮生长因子受体 2 阴性乳腺癌的成本效果分析。
J Manag Care Spec Pharm. 2021 Mar;27(3):327-338. doi: 10.18553/jmcp.2021.27.3.327.
9
Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.瑞波西利用于治疗晚期激素受体阳性、HER2 阴性乳腺癌。
Future Oncol. 2017 Oct;13(24):2137-2149. doi: 10.2217/fon-2017-0183. Epub 2017 Jul 31.
10
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial.来曲唑联合或不联合瑞博西林（ribociclib）治疗激素受体阳性、人表皮生长因子受体 2 阴性晚期乳腺癌的多中心、随机、开放标签的 III 期 MONALEESA-3 临床试验
Breast Cancer Res. 2018 Oct 19;20(1):123. doi: 10.1186/s13058-018-1050-7.

引用本文的文献

1
Targeted therapies induced depigmentation: a review.靶向治疗引起的色素脱失：综述
Front Immunol. 2025 Aug 8;16:1625738. doi: 10.3389/fimmu.2025.1625738. eCollection 2025.
2
Vitiligo-Like Depigmentation Induced by Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Metastatic Breast Cancer: A Case Report and Literature Review.细胞周期蛋白依赖性激酶4/6抑制剂治疗转移性乳腺癌所致白癜风样色素脱失：1例报告及文献复习
Cureus. 2025 May 5;17(5):e83513. doi: 10.7759/cureus.83513. eCollection 2025 May.
3
A post-marketing disproportionality analysis of the safety of ribociclib based on the FDA Adverse Event Reporting System.

本文引用的文献

1
Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System.乳腺癌中细胞周期蛋白依赖性激酶 4/6 抑制剂的皮肤毒性：来自 FDA 不良事件报告系统的不适当性分析信号。
Am J Clin Dermatol. 2022 Mar;23(2):247-255. doi: 10.1007/s40257-021-00645-0. Epub 2021 Oct 26.
2
Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review.新型细胞周期蛋白依赖性激酶4/6抑制剂治疗乳腺癌患者出现的新发皮肤毒性：一项系统评价
Drug Saf. 2021 Jul;44(7):725-732. doi: 10.1007/s40264-021-01071-1. Epub 2021 May 6.
3
基于美国食品药品监督管理局不良事件报告系统的瑞博西尼安全性上市后不均衡性分析。
Ther Adv Drug Saf. 2025 Feb 28;16:20420986251324633. doi: 10.1177/20420986251324633. eCollection 2025.
Ribociclib-Induced Erythema Dyschromicum Perstans (Ashy Dermatosis)-Like Pigmentation in a Metastatic Breast Cancer Patient.
瑞博西尼诱发转移性乳腺癌患者出现持久性红斑黑变病（灰皮病）样色素沉着。
J Breast Cancer. 2021 Feb;24(1):117-121. doi: 10.4048/jbc.2021.24.e1.